3Legs Resources Share Discussion Threads

[5baggersrus] 30/9/2015 07:53

New investment and results today, overheads remain low and a decent wedge of cash still to be invested before Nov.

One to tuck away

[the stigologist] 19/8/2015 23:07

5 shags how is the ramping going here ? Hope you recover some of your WRN losses

[5baggersrus] 19/8/2015 08:20

Good volume early on...might see a decent breakout regardless of news

[monkeyspanker2000] 18/8/2015 16:07

Good Buying. a 1.4m on isdx to add. this is poised to blow.
Central nic profits re-invested here ;)
Old Akers taken 3% of AVP ....This has Billionaires behind it though!!

Life Sciences is uber hot sector. I've done my research here and will not sell till way up.

[5baggersrus] 18/8/2015 11:16

Mann Bioinvest Launches Pathfinder Fund Targeting Life Science Growth Firms

St Helier, Jersey/Douglas, Isle of Man – August 4, 2015 – Mann Bioinvest, the Isle of Man-headquartered specialist life science advisory company chaired by renowned investor Jim Mellon, has launched a new global investment fund focused on small-cap and private companies in the therapeutic sector.

Mann Bio Pathfinder IC (MBP)– is the firm’s second life sciences vehicle and will be managed by chief investment officer Andy Smith, whose track record in the sector is well established – Smith’s existing fund with Mann Bioinvest, the Magna Biopharma Income Fund (MBIF), is up over 50% in the 19 months since inception.

“We believe the life science sector is entering a secular growth phase that will eclipse the golden age of pharmaceutical drug development in the 1990s,” says Smith. “Forty one new drugs were approved by the Federal Drug Administration in 2014, an 18-year high.”

Small-cap and Private Companies Undervalued
Although there has been a run-up in valuations of mid- and large-cap life science firms, Smith and the Mann Bioinvest team continue to see significant value in small-cap and private life science companies where greater diligence is needed to determine value. Furthermore, many life science funds previously investing in small-cap and private companies have withdrawn as the market has become increasingly focused on larger, listed companies.

Unlike its sister fund MBIF, MBP will be investing for growth not income. It will deploy a cross-over strategy, ready to invest at all but the earliest (and most risky) stages of drug development. Fund size will be £100 million, with a minimum investment of £1,000,000.

Strong Pipeline of Innovative Companies
MBP’s targets will be life science companies with innovative and specialty products with the greatest chance of clinical, regulatory and commercial success, including biotechnology, pharmaceuticals, medical devices and diagnostics. The team will deploy an activist approach where appropriate, and will tend to invest for the long term. The investment team has already identified a strong pipeline of potential opportunities and also benefits from deal-flow due to the global investor network of Jim Mellon.

A Pedigree CIO
Smith brings an extensive track record of life science investment expertise across multiple investment firms (including AXA Framlington Biotech Fund, Bioscience Investment Trust and International Biotechnology Trust), different technologies, various therapeutic areas and disparate geographies. With a PhD in molecular biology, Smith has direct industry experience working in R&D and commercial roles for companies such as ICI, Glaxo and SmithKlineBeecham Pharmaceuticals, including managing a successful pharmaceutical brand with £130 million in annual sales. He was awarded techMark Technology Fund Manager of the Year in 2007.

When combined with the experience of the remaining investment team, this deep knowledge of science, investment, product development and marketing not only adds unique value to the selection process but also means MBP can provide strategic guidance and advice to investee companies to aid their growth.

Capitalising on Demographic and Technological Momentum
Although valuations in some parts of the sector may be reaching their peak in the short term, Smith, Mellon and the Mann Bioinvest team believe that, with demographic and technological momentum in its favour, the sector as a whole has major long-term potential. Skilled investors can extract extra value from a long-term approach to early-stage companies.

“The fund stands to benefit from major secular changes, in particular the increasing incidence of lifestyle diseases associated with high-calorie diets, type-2 diabetes and the associated co-morbidities. This will compound the increasing social costs of an ageing population, in both developed and emerging economies, which are characterized by a rapidly deteriorating dependency ratio (the relationship of the non-working to working as the population ages). The predictable consequence will be an increased spend, both through private and public healthcare systems, on tools, techniques and treatments that will reduce suffering, enhance lifestyles and improve clinical outcomes,” says Smith.

[goodbloke1] 18/8/2015 08:10

Stig unfortunately has no life but to deramp.Let him be.Its his only pleasure!No one takes him seriously

[5baggersrus] 17/8/2015 11:34

removed the LT chart as it is pretty irrelevant given the capital return and change to life science investment / RTO company..

[tees maar khan] 16/8/2015 17:06

No problemo (",)TMK

[bumpa33] 16/8/2015 16:47

Sorry Tees, that came across a bit short, wasn't meant to be ;)

[tees maar khan] 16/8/2015 15:46

Thank you for stating the obvious.TMK

[bumpa33] 16/8/2015 13:47

capital returns to shareholders - read the RNS's from the beginning of the year.

[tees maar khan] 16/8/2015 12:28

Hi, I've just taken a look at that chart. Could someone please tell me, what's the reason for that big decline?TMK

[monkeyspanker2000] 14/8/2015 14:59

Going to pop !

[the stigologist] 14/8/2015 11:42

duh altruism

[bumpa33] 14/8/2015 10:27

Stig - what the hell is the point you being on these boards?

Are you here to make money or just slag everything and everyone off? I don't recall ever seeing you post anything positive on anything(!) in all your incarnations over the years - if you took your head out of the sand and quit the personal diatribes you might find some real purpose to these boards, either long or short.

[5baggersrus] 14/8/2015 10:22

you really are a clueless idiot

[the stigologist] 14/8/2015 10:11

lol you can lie as much as you want but you hung around for ages on a thread of a suspended stock before admitting defeat

that is a LOSS whether you admit it or not

[the stigologist] 14/8/2015 09:42

ramping on the pump and dump thread

tut tut

trying to make up your WRN losses hey

5baggersrus
14 Aug'15 - 09:17 - 528881 of 528887 1 0

3LEG still moving forward for those with a longer term investment pot.....volume picking up since the AGM approval and change of investment policy

[5baggersrus] 14/8/2015 09:13

volume and price gradually improving over the last weeks .... nice and steady and one to put away imo knowing the company is in good hands .... and you are invested in something that is more than drilling holes in the ground !!!!!!!!

[kingston78] 13/8/2015 17:59

This is the type of shares that will attract the attention of investors when a transforming deal has been done. It is worth including this as part of your portfolio because one day the share price will shoot up without warning. Your patience will be rewarded.

[monkeyspanker2000] 13/8/2015 04:58

take your positions boys

[5baggersrus] 12/8/2015 21:57

As you know mate good....while u was being an idiot we were buying in the 20's before a 10 bagger xxx

[the stigologist] 12/8/2015 18:47

5shags how is your WRN treating ya

pmsl